Publications by authors named "Arif Hanafi"

Background And Aim: Non-small cell lung cancer (NSCLC) is the most common lung cancer found in elderly patients. Aging and chronic inflammation are related to its pathogenesis. Functional status, lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio describe a chronic inflammation and correlate to the survival of older adults with advanced-stage (IIIB-IV) NSCLC.

View Article and Find Full Text PDF
Article Synopsis
  • Advances in molecular biology and high-throughput tests are enhancing lung cancer management by identifying genetic variations in patients.* -
  • A study analyzing 627 tissue samples and 80 liquid biopsy samples from lung cancer patients revealed various EGFR variants using RT-PCR and next-generation sequencing (NGS).* -
  • The results indicated that EGFR variants are prevalent, and liquid biopsy with ctDNA can uncover a wider range of genetic variations, which is crucial for tailoring treatment plans.*
View Article and Find Full Text PDF
Article Synopsis
  • Most patients with advanced non-small cell lung cancer (NSCLC) have a poor survival rate, and the study investigates how nutritional status impacts treatment response and overall survival in these patients.
  • The study followed 174 patients with stage II-IV NSCLC over two years, revealing that only a small percentage achieved a complete response to treatment, and the median survival was 12 months.
  • Findings indicated that being male and overweight or obese are linked to lower survival rates, regardless of other factors like age, disease stage, and baseline health.
View Article and Find Full Text PDF
Article Synopsis
  • - Lung cancer is a leading cause of cancer-related deaths among men, necessitating a biological marker for better treatment outcomes in non-small cell lung cancer (NSCLC) patients, particularly in Indonesia.
  • - A retrospective cohort study analyzed various blood test results (e.g., hemoglobin, leukocytes, tumor markers) to assess their impact on the survival rate of NSCLC patients.
  • - Significant findings indicated that poor prognostic factors include advanced performance status, late TNM stage, high white blood cell counts, low platelets, and other lab abnormalities, with the need for more research on their correlatives.
View Article and Find Full Text PDF

Objective: This study aims to evaluate the correlation between electrolytes and serial miRNAs from our previous study. We want to prove that there is the molecular basis that underlying electrolytes disturbances as the predictive indicator to the outcome in NSCLC patients.

Results: There were positive correlation between potassium level with miR-34 (p  = 0.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the potential of the FIB-4 index as a predictor of mortality in patients with both hematological malignancies and COVID-19, focusing on finding an optimal cut-off value.
  • Conducted at Dharmais National Cancer Hospital in Indonesia, it analyzed 70 patients and found a significant correlation between higher FIB-4 values and increased mortality risk over a 3-month period.
  • The results indicated that a FIB-4 index greater than 3.85 had strong predictive power for mortality, with implications for patient management and treatment decisions.
View Article and Find Full Text PDF

Background: Lung cancer is the most common cause of death in men in the world and in Indonesia where non-small cell carcinoma lung cancer (NSCLC) constitutes 85% of all lung cancer cases. The high mortality rate is due to a poor prognosis and is often diagnosed as having advanced stages. If it is known at the initial stage, the prognosis of lung cancer will be better.

View Article and Find Full Text PDF
Article Synopsis
  • The study compares the effectiveness of three EGFR-tyrosine kinase inhibitors (gefitinib, erlotinib, and afatinib) in treating advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations in Indonesia.
  • It involved a retrospective analysis of 88 NSCLC patients, focusing on outcomes like treatment response and progression-free survival (PFS), finding no significant differences in PFS among the three treatments.
  • The results indicated that while afatinib may be linked to a longer PFS, all three treatments were similarly effective overall, suggesting the need for more research.
View Article and Find Full Text PDF